Back to Search Start Over

Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5 years.

Authors :
Stepien, Karolina M.
Hendriksz, Christian J.
Roberts, Mark
Sharma, Reena
Source :
Molecular Genetics & Metabolism. Apr2016, Vol. 117 Issue 4, p413-418. 6p.
Publication Year :
2016

Abstract

Pompe disease is an autosomal recessive disease resulting from deficiency of the acid alpha-glucosidase (GAA). The late-onset Pompe Disease (LOPD) patients develop muscular and respiratory complications later in life. We describe a retrospective observational cohort study including 22 patients with LOPD. The cohort was assessed at baseline before Enzyme Replacement Therapy (ERT) with alglucosidase alpha (20 mg/kg biweekly) was commenced and subsequently relevant information was collected at 2, 4 and 5 years later. The median age of the patients at study entry was 44 years (16–64 years), with median disease duration of 11.5 years (4–31 years). At baseline, 10 patients (45%) could walk without support, 12 (55%) could walk with unilateral or bilateral support including 3/12 were wheelchair bound. Mean predicted FVC % was 55.7 (95% CI 45–66) of predicted normal at baseline and showed no significant change after 5 years (54.6 (95% CI 43–66)), (all p = 0.9815). Mean FVC % supine was 41.8 (95% CI 33.8–49) of predicted normal at baseline and remained significantly unchanged at 5 years (48.4 (95% CI 37–59.6)), (all p = 0.8680). The overnight non-invasive ventilator dependence increased by 18.2% as compared with baseline and requirement of mobility aids increased during this period by 5.2% as compared with the baseline. Mean walking distance at 6 min walk test was 411.5 (95% CI 338–485) at baseline, 266.5 (95% CI 187–346) m at 2 years, 238.6 (95% CI 162–315) m at 4 years and 286.8 (95% CI 203–370) m at 5 years ( p = 0.1981; ANOVA was completed only for 14 patients). A gradual decline in FVC% predicted was noted only in four cases and a decline in FVC% supine in two other. Only one patient showed a decline in both pulmonary function tests. In all remaining cases (17/22) respiratory function remains stable. In conclusion overall pulmonary function tests and mobility remained stable for 5 years in majority of patients on ERT. However, in some patients they continued to decline in spite of ERT resulting in increased number of patients requiring ventilation and increase wheel chair dependence at the end of 5 years. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10967192
Volume :
117
Issue :
4
Database :
Academic Search Index
Journal :
Molecular Genetics & Metabolism
Publication Type :
Academic Journal
Accession number :
114133037
Full Text :
https://doi.org/10.1016/j.ymgme.2016.01.013